Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study

European Journal of Surgical Oncology

Volumn 41, Issue 4, 2015, Pages 499-505

  Malik, H ^a   Khan, A Z ^b   Berry, D P ^c   Cameron, I C ^d   Pope, I ^e   Sherlock, D ^f   Helmy, S ^g   Byrne, B ^h   Thompson, M ⁱ   Pulfer, A ^j   Davidson, B ^g  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^e UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^f PENNINE ACUTE HOSPITALS NHS TRUST   (United Kingdom)

^g ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^h Merck Serono Ltd   (United Kingdom)

ⁱ Formerly of Merck Serono Ltd   (United Kingdom)

^j PH ASSOCIATES   (United Kingdom)

more..

Author keywords

Cetuximab; Colorectal cancer; Downsizing chemotherapy; Liver resection

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINATE CALCIUM; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; RALTITREXED; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DOWNSIZING CHEMOTHERAPY; FEMALE; HUMAN; HUMAN TISSUE; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; OBSERVATIONAL STUDY; ONCOGENE K RAS; PRIORITY JOURNAL; UNITED KINGDOM; WILD TYPE; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; ANALOGS AND DERIVATIVES; COLORECTAL TUMOR; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GREAT BRITAIN; HEPATECTOMY; HUMANS; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM, RESIDUAL; ORGANOPLATINUM COMPOUNDS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR BURDEN;

EID: 84929942462     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2015.01.032     Document Type: Article

References (19)

1. Lam VW, Spiro C, Laurence JM, et al. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol 2012 Apr;19(4):1292-301.
2. Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien PA. Chemotherapy before liver resection of colorectal metastases: friend or foe? Ann Surg 2012 Feb;255(2):237-47.
3. Nordlinger B, Adam R, Arnold D, Zalcberg JR, Gruenberger T. The role of biological agents in the resection of colorectal liver metastases. Clin Oncol R Coll Radiol 2012 Aug;24(6):432-42.
4. National Institute for Health and Clinical Excellence. Colorectal cancer (first line) e cetuximab (TA176) June 2009. http://publications.nice.org.uk/cetuximab-for-the-first-line-treatment-of-metastaticcolorectal-cancer-ta176. [accessed 03.12.13].
5. Scottish Medicines Consortium. SMC advice: cetuximab (Erbitux) 8 Feb 2010. Available at: http://www.scottishmedicines.org.uk/SMC-Advice/Advice/543-09-cetuximab--Erbitux-/cetuximab--Erbitux-1. [accessed 03.12.13].
6. Merck Serono. Summary of Product Characteristics, Erbitux 5 mg/ml solution for infusion. Available at: https://www.medicines.org.uk/emc/medicine/19595 [accessed 14.08.14].
7. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38-47.
8. Ye L-C, Liu T-S, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 2013;31(16):1931-8.
9. Garrison Jr LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health 2007 Sep-Oct; 10(5):326-35.
10. Health Research Authority. Governance arrangements for research ethics committees (GAfREC) May 2011. Available at: http://www.nres.nhs.uk/nres-publications/news/governance-arrangements-forresearch-ethics-committees/. [accessed 03.12.13].
11. Data Protection Act. s33 research exemption 1998. Available at: http://www.legislation.gov.uk/ukpga/1998/29/section/33. [accessed 03.12.13].
12. Ayez N, Lalmahomed ZS, Eggermont AM, et al. Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann Surg Oncol 2012 May; 19(5):1618-27.
13. Primrose J, Falk S, Finch-Jones M, et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the new EPOC randomised controlled trial. Lancet Oncol 2014 May;15(6):601-11.
14. Morris EJA, Forman D, Thomas D, et al. Surgical management and outcomes of colorectal cancer liver metastases. Br J Surg 2010;97:1110-8.
15. Folprecht G, Gruenberger T, Bechstein W, et al. Cetuximab and chemotherapy in the treatment of patients with initially "nonresectable" colorectal (CRC) liver metastases: long-term follow-up of the CELIM trial. J Clin Oncol 2013;31. [suppl; abstr 3538].
16. Jones RP, Vauthey JN, Adam R, et al. Effect of specialist decisionmaking on treatment strategies for colorectal liver metastases. Br J Surg 2012 Sep;99(9):1263-9.
17. Douillard J-Y, Oliner KS, Siena S, et al. PanitumumabeFOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013;369:1023-34.
18. Ciardiello F, Lenz HJ, Kohne CH, et al. Effect of KRAS and NRAS mutational status on first-line treatment with FOLFIRI plus cetuximab in patients with metastatic colorectal cancer (mCRC): new results from the CRYSTAL trial. J Clin Oncol 2014;32. [suppl 3; abstr LBA443].
19. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1065-75. http://dx.doi.org/10.1016/S1470-2045(14)70330-4.